
First published in the *Government Gazette*, Electronic Edition, on 29 November 2019 at 5 pm.

No. S 791

MISUSE OF DRUGS ACT (CHAPTER 185)

MISUSE OF DRUGS (AMENDMENT NO. 4) REGULATIONS 2019

In exercise of the powers conferred by section 58(1) of the Misuse of Drugs Act, the Minister for Home Affairs makes the following Regulations:

Citation and commencement

1. These Regulations are the Misuse of Drugs (Amendment No. 4) Regulations 2019 and come into operation on 1 December 2019.

Amendment of Fourth Schedule

2. The Fourth Schedule to the Misuse of Drugs Regulations (Rg 1) is amended —

(a) by inserting, immediately after item (10) of paragraph 1, the following item:

“(11) N,N-Diethyl-3-hydroxy-7-methyl-2-oxo-4,6,6a,7,8,9-hexahydroindolo-[4,3-*fg*]quinoline-9-carboxamide (also known as 2-Oxo-3-hydroxy-LSD) and its acyclic secondary and tertiary amide structural isomers”;

(b) by deleting items (13), (14) and (15) of paragraph 1 and substituting the following items:

“(13) 2,5-Dimethoxy- α -methylphenethylamine (also known as 2,5-Dimethoxyamphetamine or DMA) and its dimethoxy positional isomers in the phenyl ring

(14) N, α -Dimethyl-3,4-(methylenedioxy)phenethylamine (also known as 3,4-Methylenedioxymethamphetamine or MDMA)

(15) 3-(1,2-Dimethylheptyl)-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran (also known as DMHP”;

(c) by deleting item (17) of paragraph 1 and substituting the following item:

“(17) 4-Ethyl-2,5-dimethoxy- α -methylphenethylamine (also known as DOET)”;

(d) by deleting item (25) of paragraph 1 and substituting the following item:

“(25) 3-Methoxy- α -methyl-4,5-(methylenedioxy)phenethylamine (also known as 5-methoxy-MDA or MMDA)”;

(e) by deleting item (28) of paragraph 1 and substituting the following item:

“(28) N-[α -Methyl-3,4-(methylenedioxy)phenethyl]hydroxylamine (also known as N-Hydroxy MDA)”;

(f) by deleting item (36) of paragraph 1 and substituting the following item:

“(36) 3,4,5-Trimethoxy- α -methylphenethylamine (also known as TMA)”;

(g) by inserting, immediately after item (8AA) of paragraph 15, the following item:

“(8AAB) 1-(4-Chlorophenyl)-2-(dimethylamino)propan-1-one (also known as 4-Chloro-N,N-dimethylcathinone)”;

(h) by deleting item (13) of paragraph 15 and substituting the following item:

“(13) 2-(Ethylamino)-1-phenylpentan-1-one (also known as α -Ethylaminopentiophenone or N-Ethylpentedrone)”;

(i) by deleting items (1), (1AAA), (1AA) and (1A) of paragraph 17 and substituting the following items:

“(1) 1-Acetyl-N,N-diethyllysergamide (also known as N-Acetyl-LSD or ALD-52) and its acyclic secondary and tertiary amide structural isomers

-
-
- (1A) N-(1-Adamantyl)-5-bromopentyl-1H-indazole-3-carboxamide (also known as 5-Bromo-APINACA or 5-Bromo-AKB48) and its bromo positional isomers in the pentyl group
- (1AA) 5-{3-[(1-Adamantyl)carbamoyl]-1H-indazole-1-yl}pentanoic acid
- (1AB) N-(1-Adamantyl)-5-chloropentyl-1H-indazole-3-carboxamide (also known as 5-Chloro-APINACA or 5-Chloro-AKB48) and its chloro positional isomers in the pentyl group
- (1AC) N-(Adamant-1-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (also known as Adamantyl CHMINACA or SGT-37)
- (1AD) N-(1-Adamantyl)-5-hydroxypentyl-1H-indazole-3-carboxamide and its hydroxy positional isomers in the pentyl group
- (1AE) N-(1-Adamantyl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (also known as FUB-APINACA or FUB-AKB48) and its fluoro positional isomers in the phenyl ring
- (1AF) N-(1-Adamantyl)-5-fluoropentyl-1H-indazole-3-carboxamide (also known as 5-Fluoro-APINACA or 5F-AKB48) and its fluoro positional isomers in the pentyl group
- (1AG) N-(1-Adamantyl)-5-fluoropentyl-1H-indole-3-carboxamide (also known as 5-Fluoro-APICA or STS-135) and its fluoro positional isomers in the pentyl group”;
- (j) by inserting, immediately after item (2A) of paragraph 17, the following items:
- “(2AA) 5-{3-[(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)carbamoyl]-1H-indazole-1-yl}pentanoic acid and its N-(1-amino-1-oxohexan-2-yl) isomers
- (2AB) 5-{3-[(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)carbamoyl]-1H-indole-1-yl}pentanoic acid and its N-(1-amino-1-oxohexan-2-yl) isomers”;
- (k) by inserting, immediately after item (2C) of paragraph 17, the following item: